Clinical trials: Diabetic Retinal Disease
- Condition Diabetic Retinal Disease
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Macular Edema
Special Drug Use Investigation of EYLEA for Diabetic Macular Edema
The objectives of this study are to investigate the safety and effectiveness of EYLEA
- Trial name
- NCT02425501
- Testing
- Aflibercept (Eylea, BAY86-5321)
- Where
- Japan
- Volunteers
- 646 people
- Sponsor
- Bayer
Ophthalmology, Macular Edema
Evaluation of Changes in Visual Acuity in Patients With Diabetic Macular Edema (DME) Starting Treatment With an Approved Anti-VEGF Therapy
POLARIS : A non-interventional study in patients with diabetic macular edema (DME) with central involvement to assess the effectiveness of existing anti-vascular endothelial growth factor (anti-VEGF) treatment regimens.
- Conditions
- Ophthalmology, Macular Edema, Macular Degeneration
- Trial name
- POLARIS (NCT01771081)
- Testing
- Ranibizumab (or other DME treatment)
- Where
- 8 sites in France, Germany and 6 more
- Volunteers
- 911 people
- Sponsor
- Bayer
Diabetic Retinopathy, Age Related Macular Degeneration
Retinal Care Data Repository
The Retinal Care Data Repository's primary objective is to make data available for Retinal Care to develop algorithms that improve the care of people with retinal diseases.
- Trial name
- NCT04794907
- Testing
- Observation
- Volunteers
- 1,000 people
- Sponsor
- Retinal Care Inc.
Retinopathy, Diabetes Mellitus
Management of Diabetes Mellitus Patients With Retinopathy
Aim of this NIS is to retrospectively document the management of diabetic patients with retinopathy in a naturalistic setting in Switzerland.
- Trial name
- NCT00828425
- Where
- 62 sites in Switzerland
- Volunteers
- 2,500 people
- Sponsor
- AstraZeneca
Age-related Macular Degeneration (AMD), Central Retinal Vein Occlusion (CRVO)
Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada
The primary objective of this study is to measure physician knowledge and understanding of the key safety information contained in the Eylea vial preparation instruction card, the intravitreal injection procedure video, and the…
- Conditions
- Age-related Macular Degeneration (AMD), Central Retinal Vein Occlusion (CRVO), Diabetic Macular Edema (DME)
- Trial name
- NCT02585401
- Testing
- Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
- Where
- Canada
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Bayer
Diabetes, Macular Edema
Research Study in Patients With Persistent Macular Edema
The purpose of this clinical research study is to evaluate the safety and effectiveness of an investigational medication to treat macular edema that persists despite current treatment methods.
- Conditions
- Diabetes, Macular Edema, Diabetic Retinopathy, Retinal Disease
- Trial name
- NCT00035906
- Testing
- DEX PS DDS®
- Where
- United States
- Volunteers
- 315 people
- Sponsor
- Allergan
Diabetic Retinopathy, DR
Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic Retinopathy
This is a prospective study designed to evaluate the long-term safety and efficacy of ABBV-RGX-314. Eligible participants are those who were previously enrolled in a clinical study of DR with and without center involved-diabetic…
- Trial name
- NCT05296447
- Testing
- Standard of Care, Aflibercept
- Where
- 20 sites in United States
- Volunteers
- 103 people
- Sponsor
- AbbVie
Retinitis Pigmentosa (RP), Age Related Macular Degeneration
Evaluating a New Peptide Therapy for Retinal Diseases: AMD, Diabetic Retinopathy, and Dystrophies
Summary of the Study This clinical trial evaluates a novel peptide-based therapy for treating retinal dystrophies, age-related macular degeneration (AMD), and diabetic retinopathy (DR).
- Conditions
- Retinitis Pigmentosa (RP), Age Related Macular Degeneration, Diabetic Retinopathy
- Trial name
- Retino (NCT06787482)
- Testing
- ACE Retino
- Where
- 2 sites in Egypt
- Volunteers
- 100 people
- Sponsor
- Ace Cells Lab Limited
Diabetic Retinopathy
A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy ,DR)
Diabetic retinopathy (DR) is a diabetes complication caused by damage to the small blood vessels inside the retina at the back of the eye. Diabetic retinopathy may cause mild vision problems or eventually blindness.
- Trial name
- ReFineDR (NCT04477707)
- Testing
- Finerenone (BAY94-8862)
- Where
- 62 sites in United States, Argentina and 13 more
- Volunteers
- 206 people
- Sponsor
- Bayer
Wet Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Wet Age Related Macular Degeneration
Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting
This study will describe the long-term safety and effectiveness, treatment patterns,and patient reported quality of life associated with ranibizumab treatment in routine clinical practice for all approved indication included in…
- Conditions
- Wet Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Wet Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
- Trial name
- LUMINOUS (NCT01318941)
- Testing
- Ranibizumab
- Where
- 463 sites in Argentina, Australia and 41 more
- Volunteers
- 30,490 people
- Sponsor
- Novartis Pharmaceuticals